tiprankstipranks
Trending News
More News >
Koninklijke Philips N.V. (NL:PHIA)
:PHIA

Koninklijke Philips N.V. (PHIA) AI Stock Analysis

Compare
3 Followers

Top Page

NL

Koninklijke Philips N.V.

(LSE:PHIA)

Rating:54Neutral
Price Target:
€21.50
▲(4.17%Upside)
Koninklijke Philips N.V. faces significant challenges with persistent net losses and declining revenues. Despite some operational and cash flow improvements, the company's financial health requires attention. The technical indicators suggest a neutral to bearish trend, and the valuation remains unattractive due to negative earnings. The company's relatively stable balance sheet provides some foundation for potential recovery, but efforts to improve profitability are paramount.
Positive Factors
Financial Performance
Philips expects higher group margin mainly driven by Connected Care.
Market Activity
Philips confirms an increase in tender activity in China for some provinces.
Negative Factors
China Market
There are continued soft expectations for the Chinese market, impacting growth.
Earnings
4Q 2024 came below expectations for Philips with 4Q sales -1% vs consensus.
Market Share
D&T performance was significantly lower than peer Siemens Healthineers, suggesting market share loss.

Koninklijke Philips N.V. (PHIA) vs. iShares MSCI Netherlands ETF (EWN)

Koninklijke Philips N.V. Business Overview & Revenue Model

Company DescriptionKoninklijke Philips N.V. operates as a health technology company in North America and internationally. It operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. The company provides diagnostic imaging solutions, includes magnetic resonance imaging, computed tomography (CT) systems, X-ray systems, and detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; integrated interventional systems; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. It also offers acute patient management solutions; emergency care solutions; sleep and respiratory care solutions; and electronic medical record and care management solutions. In addition, the company provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding and digital parental solutions; and male grooming and beauty products and solutions. It has a strategic collaboration with Ibex Medical Analytics Ltd. to jointly promote the digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide, as well as a strategic partnership agreement with NICO.LAB. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.
How the Company Makes MoneyPhilips generates revenue through its three primary business segments: Diagnosis & Treatment, Connected Care, and Personal Health. The Diagnosis & Treatment segment provides advanced imaging systems, ultrasound, and image-guided therapy solutions, catering primarily to hospitals and healthcare professionals. Connected Care focuses on comprehensive patient care solutions, including patient monitoring and health informatics, designed to improve care delivery and patient outcomes. The Personal Health segment offers consumer health products such as oral healthcare, mother and child care, and personal care appliances, targeting individual consumers. Philips also leverages strategic partnerships and collaborations with healthcare providers, technology companies, and research institutions to expand its market reach and enhance its product offerings, contributing to its overall revenue growth.

Koninklijke Philips N.V. Financial Statement Overview

Summary
Koninklijke Philips N.V. is navigating a challenging period characterized by declining revenues and persistent net losses. While operational margins and cash flow management show signs of improvement, the company must address its profitability issues to bolster financial health. The balance sheet remains relatively robust, providing a foundation for potential recovery.
Income Statement
65
Positive
The income statement shows a mixed performance. While the gross profit margin improved slightly in 2024 compared to 2023, at 43.1% versus 41.0%, the company has struggled with net profitability, recording negative net income for the past three years. Revenue growth was negative at -0.8% from 2023 to 2024, reflecting a challenging market environment. The EBIT margin improved to 2.9% in 2024 from negative figures in prior years, indicating some operational improvements.
Balance Sheet
70
Positive
The balance sheet reveals moderate financial stability. The debt-to-equity ratio in 2024 is approximately 0.62, indicating a manageable level of leverage. Stockholders' equity has remained relatively stable, although total assets have decreased slightly. The equity ratio stands at around 41.5%, suggesting a solid equity base. However, persistent losses could pressure future equity levels.
Cash Flow
60
Neutral
Cash flow analysis shows some recovery. Free cash flow increased to 893 million in 2024 from 1493 million in 2023, signaling improved cash management. However, the free cash flow to net income ratio is negative due to net losses. The operating cash flow to net income ratio is positive, highlighting the ability to generate cash despite accounting losses.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue17.98B18.02B18.17B17.83B17.16B19.54B
Gross Profit7.81B7.77B7.45B7.19B7.17B8.78B
EBITDA1.73B1.85B1.04B-280.00M1.73B2.56B
Net Income373.00M-702.00M-466.00M-1.62B612.00M1.19B
Balance Sheet
Total Assets27.17B28.98B29.41B30.69B30.96B27.71B
Cash, Cash Equivalents and Short-Term Investments1.20B2.40B1.87B1.18B2.31B3.23B
Total Debt7.57B7.49B7.69B8.20B6.98B6.93B
Total Liabilities15.44B16.93B17.34B17.41B16.49B15.81B
Stockholders Equity11.70B12.01B12.03B13.25B14.44B11.87B
Cash Flow
Free Cash Flow-20.00M893.00M1.49B-979.00M866.00M1.83B
Operating Cash Flow807.00M1.57B2.14B-173.00M1.63B2.78B
Investing Cash Flow-320.00M-573.00M-636.00M-1.49B-3.67B-1.32B
Financing Cash Flow425.00M-496.00M-848.00M500.00M-2.35B483.00M

Koninklijke Philips N.V. Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price20.64
Price Trends
50DMA
20.62
Negative
100DMA
21.99
Negative
200DMA
23.57
Negative
Market Momentum
MACD
-0.17
Negative
RSI
54.11
Neutral
STOCH
83.01
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NL:PHIA, the sentiment is Neutral. The current price of 20.64 is above the 20-day moving average (MA) of 20.12, above the 50-day MA of 20.62, and below the 200-day MA of 23.57, indicating a neutral trend. The MACD of -0.17 indicates Negative momentum. The RSI at 54.11 is Neutral, neither overbought nor oversold. The STOCH value of 83.01 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NL:PHIA.

Koninklijke Philips N.V. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
€19.61B-7.02%3.60%-0.81%-54.90%
51
Neutral
$7.41B0.36-61.88%2.34%16.99%1.69%
$742.99M-6.31%
€1.58B19.97-6.36%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
NL:PHIA
Koninklijke Philips N.V.
20.64
-2.03
-8.96%
PHGUF
Pharming Group
1.10
0.29
35.80%
GB:0JXZ
Galapagos
24.24
0.83
3.55%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 20, 2025